Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000280

Drug Information
NameBrimonidine    
SynonymsNCGC00023468-04; 5-brom-n-(4,5-dihydro-1h-imidazol-2-yl)chinoxalin-6-amin; ZINC21303210; U104_SIGMA; MLS001076349; AC-162; UK 14,304-18; Brimonidine [INN:BAN]; MLS000069370; CID2435; UK 14308; NCGC00023468-07; L000615; NCGC00016069-01; AR-1G7332; SAM002548958; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; Tocris-0425; Lopac0_001216; UK 14304; U-104; Bromoxidine; NCGC00023468-05; 59803-98-4; 70359-46-5 (tartrate[1:1]); 5-bromo-6-(imidazolidinylideneamino)quinoxaline; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI); PDSP1_000640; 5-Bromo-N-(2-imidazolin-2-yl)-6-quinoxalinamine; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; Brimonidine (INN); AC1Q26LW; nchembio705-7; FT-0082636; NCGC00016069-02; C11H10BrN5; 5-bromo-6-(imidazolin-2-ylamino)quinoxaline; UK 14304-18; UNII-E6GNX3HHTE; brimonidina; NCGC00016069-06; CPD000058355; AGN 190342; LK 14304-18; CHEMBL844; NCGC00023468-02; D07540; brimonidinum; Lopac-U-104; CHEBI:3175; BRN 0751629; T6531398; UK 14,304; BIDD:GT0649; NSC318825; DB00484; MolPort-003-959-841; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; NCGC00016069-11; AGN-190342; AC1L1DO5; C07886; UK-14,304-18; PDSP2_000635; NCGC00023468-06; LS-142950; SMR000058355; AC1Q24IC; UK-14304; brimonidine; EU-0101216; UK-14,308    
Trade NameAlphagan; Alphagan-P    
CompanyAllergan Pharmaceuticals    
IndicationOpen-angle glaucoma and ocular hypertensionApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntihypertensive Agents    
CAS NumberCAS 59803-98-4
FormularC11H10BrN5    
PubChem Compound IDCID 2435.    
PubChem Substance IDSID 10088.    
ChEBI3175;    
SuperDrug ATC IDS01EA05;    
SuperDrug CAS ID059803984;    
TargetAlpha-2A adrenergic receptorAgonist[2][3][4]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway. Biochem Pharmacol. 2000 Jun 15;59(12):1531-8. To Reference
Ref 3Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. To Reference
Ref 4Decreased density of presynaptic alpha 2-adrenoceptors in postmortem brains of patients with Alzheimer's disease. J Neurochem. 1992 May;58(5):1896-904. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543